Lonza, a pharmaceutical manufacturing specialist, has appointed Wolfgang Wienand as the CEO of the group.
Wolfgang succeeds Albert M. Baehny, who was the ad interim CEO from October 2023 and the Chairman of the Board of Directors from 2018 to May 2024.
Wienand has worked in the CDMO industry for almost 20 years, and will focus on meeting and exceeding the needs of customers by building on the company’s growth and expanding its service offerings.
Since 2019, Wolfgang has held the role of CEO at the Swiss CDMO Siegfried.
Wolfgang previously served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team.
Prior to joining Siegfried in 2010, Wolfgang held a series of positions with increasing seniority at the German specialty chemicals company Evonik Industries.
Jean-Marc Huët, Chairman of the Board of Directors, Lonza, commented: “On behalf of the Board, I extend a warm welcome to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his leadership.”
